Abstract
SRY-negative 46,XX testicular disorders of sex development (DSD) are very rare conditions. Recently, we identified a novel heterozygous NR5A1 mutation, p.Arg92Trp (c.274C>T, p.R92W), in 2 unrelated cases of 46,XX testicular/ovotesticular DSD. We report the clinical course from infancy to puberty in a Japanese male with SRY-negative 46,XX testicular DSD, carrying this p.Arg92Trp mutation in NR5A1. The patient naturally acquired the development of a penis and pubic hair during puberty. However, hypergonadotropic hypogonadism subsequently developed. More clinical cases will be needed to fully understand the effects of the p.Arg92Trp mutation on the ability to maintain testosterone secretion in 46,XX testicular DSD.
References
1.
Baetens D, Mladenov W, Chiaie BD, Menten B, Desloovere A, et al: Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development. Orphanet J Rare Dis 9:209 (2014).
2.
Baetens D, Stoop H, Peelman F, Todeschini AL, Rosseel T, et al: NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development. Genet Med 19:367-376 (2017).
3.
Bashamboo A, Donohoue PA, Vilain E, Rojo S, Calvel P, et al: A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet 25:3446-3453 (2016).
4.
Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, et al: Ten novel mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency in 46,XX individuals. J Clin Endocrinol Metab 97:E1294-1306 (2012).
5.
Cox JJ, Willatt L, Homfray T, Woods CG: A SOX9 duplication and familial 46,XX developmental testicular disorder. N Engl J Med 364:91-93 (2011).
6.
Fukami M, Ogata T: Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects. Pediatr Int 56:805-808 (2014).
7.
Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, et al: Cytochrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 90:414-426 (2005).
8.
Hatano M, Migita T, Ohishi T, Shima Y, Ogawa Y, et al: SF-1 deficiency causes lipid accumulation in Leydig cells via suppression of STAR and CYP11A1. Endocrine 54:484-496 (2016).
9.
Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES1/ESPE2 Consensus Group: Consensus statement on management of intersex disorders. Arch Dis Child 91:554-563 (2006).
10.
Igarashi M, Takasawa K, Hakoda A, Kanno J, Takada S, et al: Identical NR5A1 missense mutations in two unrelated 46,XX individuals with testicular tissues. Hum Mutat 38:39-42 (2017).
11.
Kirsch S, Weiss B, Zumbach K, Rappold G: Molecular and evolutionary analysis of the growth-controlling region on the human Y chromosome. Hum Genet 114:173-181 (2004).
12.
Lee GM, Ko JM, Shin CH, Yang SW: A Korean boy with 46,XX testicular disorder of sex development caused by SOX9 duplication. Ann Pediatr Endocrinol Metab 19:108-112 (2014).
13.
Mandel H, Shemer R, Borochowitz ZU, Okopnik M, Knopf C, et al: SERKAL syndrome: an autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am J Hum Genet 82:39-47 (2008).
14.
Mizuno K, Kojima Y, Kamisawa H, Moritoki Y, Nishio H, et al: Elucidation of distinctive genomic DNA structures in patients with 46,XX testicular disorders of sex development using genome wide analyses. J Urol 192:535-41 (2014).
15.
Morohashi K, Omura T: Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function. FASEB J 10:1569-1577 (1996).
16.
Nishina-Uchida N, Fukuzawa R, Numakura C, Suwanai AS, Hasegawa T, et al: Characteristic testicular histology is useful for the identification of NR5A1 gene mutations in prepubertal 46,XY patients. Horm Res Paediatr 80:119-128 (2013).
17.
Parma P, Radi O, Vidal V, Chaboissier MC, Dellambra E, et al: R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet 38:1304-1309 (2006).
18.
Prince FP: The triphasic nature of Leydig cell development in humans, and comments on nomenclature. J Endocrinol 168:213-216 (2001).
19.
Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC: DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Pract Res Clin Endocrinol Metab 29:607-619 (2015).
20.
Vetro A, Ciccone R, Giorda R, Patricelli MG, Della Mina E, et al: XX males SRY negative: a confirmed cause of infertility. J Med Genet 48:710-712 (2011).
21.
Vorona E, Zitzmann M, Gromoll J, Schüring AN, Nieschlag E: Clinical, endocrinological, and epigenetic features of the 46,XX male syndrome, compared with 47,XXY Klinefelter patients. J Clin Endocrinol Metab 92:3458-3465 (2007).
22.
Wu QY, Li N, Li WW, Li TF, Zhang C, et al: Clinical, molecular and cytogenetic analysis of 46,XX testicular disorder of sex development with SRY-positive. BMC Urol 14:70 (2014).
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.